NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
5/8 — Partial
MIEBO (perfluorohexyloctane) by Bausch + Lomb is perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. First approved in 2023.
Drug data last refreshed 19h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIEBO (perfluorohexyloctane) is a semifluorinated alkane ophthalmic solution approved by the FDA in May 2023 for dry eye disease (DED). It works by forming a monolayer at the air-liquid interface of the tear film to reduce tear evaporation, though the exact mechanism remains incompletely understood. This represents a novel chemical class with a fundamentally different approach to managing DED.
$0.009BPart D
Peak10.7 years to LOEEarly-stage peak adoption with modest Medicare spending ($9M in 2023) suggests a small but growing commercial footprint; team building and market expansion remain priorities.
Mechanism of Action
Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is…
Pharmacologic Class:
Semifluorinated Alkane
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo®
Started Jun 2026
20 enrolled
Dry Eye
A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK
Started May 2026
100 enrolled
Dry Eye Syndrome (DES)Dry Eye Disease (DED)
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Started Feb 2026
269 enrolled
Dry Eye Disease (DED)
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Started Dec 2025
0Dry Eye Disease
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
Started Jul 2025
104 enrolled
Dry Eye
Worked on MIEBO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.